Scientists identify two key genes linked to aggressive breast cancers

September 15, 2005

(Toronto - September 15, 2005) - In a new study, scientists at The Hospital for Sick Children and Princess Margaret Hospital have shown that two genes called Notch1 and Jagged1 are linked to more aggressive breast cancers and that patients are less likely to survive the disease when these two genes are highly expressed.

The study is published in the September 15th issue of the journal Cancer Research, a publication of the American Association for Cancer Research.

"These two genes are likely markers indicating a patient's probable prognosis," says the study's principal investigator Dr. Sean Egan, senior scientist at The Hospital for Sick Children and associate professor of molecular and medical genetics at the University of Toronto. "Now we can develop a way of screening for these markers, which may help physicians determine how best to treat patients."

Notch1 and Jagged1 are players in the Notch signalling pathway, which is normally involved in cell communication, division, differentiation, survival, and self-renewal. The scientists' work suggests that the Notch pathway may be overactive in some aggressive breast cancers.

"We're excited by this discovery because there are drugs already in development that interfere with the Notch pathway," says the study's lead author Dr. Michael Reedijk, surgical oncologist in the breast cancer program at Princess Margaret Hospital and assistant professor of surgery at the University of Toronto. "We're benefiting from 10 years of research that's been done on generating drugs to treat Alzheimer's disease. These drugs inhibit an enzyme called gamma secretase, which is likely responsible for the build up of amyloid plaques in the brains of patients with Alzheimer's disease. As Notch signalling also depends on gamma secretase, these drugs may be useful in treating Notch-dependant cancers."

The scientists examined tumour samples from 184 breast cancer patients with different prognoses and compared the gene expressions with each patient's outcome. Patients with high levels of Jagged1 had a five-year survival rate of 42% and an average survival of 50 months, compared to patients with low levels of Jagged1 who had a five-year survival rate of 65% and an average survival of 83 months.

Patients with high levels of Notch1 had a five-year survival rate of 49% and an average survival of 53 months, whereas patients with low levels of Notch1 had a five-year survival rate of 64% and an average survival of 91 months.

Patients with combined high levels of Jagged1 and Notch1 had a significantly reduced five-year survival rate of 34% and an average survival of 43 months.

Breast cancer is the most commonly diagnosed cancer and a leading cause of cancer death. The Canadian Cancer Society estimates that 21,600 women will be diagnosed with breast cancer and 5,300 will die of the disease in 2005. One in nine women will develop breast cancer during her lifetime, and one in 27 women will die from breast cancer.
-end-
This research is supported by funds from The Terry Fox Foundation and SickKids Foundation. Dr. Reedijk holds the James Ewing Oncology Fellowship for Basic Research from the Society of Surgical Oncology. He is supported by the Departments of General Surgery at University Health Network and Mount Sinai Hospital and by the Department of Surgery at the University of Toronto. SickKids Foundation provided salary and infrastructure support to Dr. Egan.

The Hospital for Sick Children, affiliated with the University of Toronto, is Canada's most research-intensive hospital and the largest centre dedicated to improving children's health in the country. Its mission is to provide the best in family-centred, compassionate care, to lead in scientific and clinical advancement, and to prepare the next generation of leaders in child health.

Princess Margaret Hospital and its research arm, Ontario Cancer Institute, have achieved an international reputation as global leaders in the fight against cancer. The Campbell Family Institute for Breast Cancer Research is the newest component of the Ontario Cancer Institute. It aims to become a world-leading program in breast cancer research by leveraging basic, translational, and clinical research into dramatic breast cancer breakthroughs. Princess Margaret Hospital is a member of the University Health Network, which also includes Toronto General Hospital and Toronto Western Hospital. All three are teaching hospitals affiliated with the University of Toronto.

For more information or to arrange an interview, please contact:
Jennifer Kohm, Public Affairs, Princess Margaret Hospital
telephone: (416) 946-2846 email: jennifer.kohm@uhn.on.ca

Laura Greer, Public Affairs, The Hospital for Sick Children
telephone: (416) 813-5046 email: laura.greer@sickkids.ca

University of Toronto

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.